ARK Invest's position in FRNM, updated every trading day. Data as of 2026-11-12.
| Fund | Shares | Value | Weight | Rank |
|---|---|---|---|---|
| ARKG | 1,839,025 | $19.5M | 0.99% | #30 |
| Trade day | Fund | Side | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-23 | ARKG | Buy | Added | 169,498 | $2.2M |
| 2026-10-22 | ARKG | Buy | Added | 35,377 | $463K |
| 2026-10-19 | ARKG | Buy | Added | 4,835 | $61K |
| 2026-10-16 | ARKG | Buy | Added | 254,668 | $3.0M |
| 2026-10-15 | ARKG | Buy | Added | 25,455 | $313K |
| 2026-10-14 | ARKG | Buy | Added | 110,037 | $1.3M |
| 2026-10-13 | ARKG | Buy | Added | 84,652 | $1.1M |
| 2026-10-12 | ARKG | Buy | Added | 136,894 | $1.8M |
| 2026-10-09 | ARKG | Buy | Added | 14,988 | $237K |
| 2026-10-08 | ARKG | Buy | Added | 67,307 | $1.1M |
| 2026-10-07 | ARKG | Buy | Added | 39,981 | $641K |
| 2026-10-06 | ARKG | Buy | Added | 35,583 | $582K |
Freenome, Inc., a biotechnology company, develops blood-based screening tests to detect cancer in the United States. The company offers an early cancer detection platform that integrates multiomics, artificial intelligence, and machine learning to uncover complex biological signals associated with cancer. It develops SimpleScreen CRC, a blood-based test, including a test for colorectal cancer screening, as well as…
See FRNM's full ARK history since 2024, ARK's estimated cost basis, the conviction score and buy/sell alerts.
Open FRNM on FundWake →Data comes from ARK Invest's public daily holdings and trade files. FundWake is not affiliated with ARK Invest. Nothing here is investment advice.